CoNCERT Pharmaceuticals Inc.*

Concert Pharmaceuticals Investor Relations Department 99 Hayden Avenue, Suite 500 Lexington, MA 02421 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: CNCE Last Trade: 14.17 Trade Time: 4:00 PM ET Aug 17, 2017 Change: -0.32 ♣ (-2.208%) Day Range 14.16 - 14.67 52-Week Range 7.11 - 19.11 Volume 97,361


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

At Concert Pharmaceuticals, we are pioneering our industryleading expertise in deuterium chemistry to discover and develop innovative drug products that have impact for patients and address important medical needs. Our innovative approach has already resulted in multiple drug candidates that offer improved ways to target a broad range of disease areas, including CNS disorders, renal disease, inflammation and cancer. Each of these novel candidates was designed to be improved with our deuterium chemistry, and is based on an approved drug, an advanced clinical candidate or a previously studied, biologically active compound.

(more)

Stock Performance



Press Releases [View all]

Aug 8, 2017

Concert Pharmaceuticals Reports Second
Quarter 2017 Financial Results and Provides
Company Update

Aug 1, 2017

Concert Pharmaceuticals to Report Second

Quarter 2017 Financial Results on August 8,

2017

Jul 25, 2017

<u>Vertex and Concert Pharmaceuticals</u> <u>Complete Asset Purchase Agreement for</u> CTP-656

Jul 24, 2017

Concert Pharmaceuticals Announces
Termination of the HSR Act Waiting Period
for CTP-656 Asset Purchase Agreement with
Vertex

Jul 10, 2017

FDA Lifts Clinical Hold on Concert
Pharmaceuticals Clinical Trial with CTP-543

Upcoming Events [View all]

Sep 6–7, 2017 2017 Wells Fargo Healthcare Conference

Nov 14–15, 2017 2017 Stifel Healthcare Conference

Financials [View all]

Apr 26, 2017
Proxy Statement (DEF 14A)

Aug 8, 2017
Quarterly Report (10-Q)

May 2, 2017 Quarterly Report (10-Q)